Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance

Amgen, Inc.Trade
Vanguard Total Stock Market Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Amgen, Inc. trades at $416.13 (market cap $224.14B), while Vanguard Total Stock Market Index Fund ETF trades at $382.16. The key difference: Amgen, Inc. pays a 2.43% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals.

AMGNVTI
Market Cap
$224.14B
Sector
Health
52-Week High
$417.20$381.78
52-Week Low
$271.18$311.68
Enterprise Value
$267.45B
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

Vanguard Total Stock Market Index Fund ETF

VTI trades at $381.95, up 0.08% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF offers broad diversification with over 3,500 holdings and a low 0.03% expense ratio, as noted by The Motley Fool on August 11, 2026. Recent institutional activity includes mixed buying and selling, with a dividend scheduled for June 30, 2026.

Outlook remains positive for long-term investors due to low costs and market-wide exposure, but risks include market volatility and concentration in large-cap tech. Analyst sentiment is generally favorable, emphasizing VTI's role in foundational portfolios, though current high RSI levels indicate potential near-term pullbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Vanguard Total Stock Market Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Read more on VTI